Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6260-6270

  Di Martino, Maria T ^a   Leone, Emanuela ^a   Amodio, Nicola ^a   Foresta, Umberto ^a   Lionetti, Marta ^b   Pitari, Maria R ^a   Gallo Cantafio, Maria E ^a   Gullà, Annamaria ^a   Conforti, Francesco ^a   Morelli, Eugenio ^a   Tomaino, Vera ^a   Rossi, Marco ^a   Negrini, Massimo ^c   Ferrarini, Manlio ^d   Caraglia, Michele ^e   Shammas, Masood A ^f,g   Munshi, Nikhil C ^f,g   Anderson, Kenneth C ^f   Neri, Antonino ^b   Tagliaferri, Pierosandro ^a   Tassone, Pierfrancesco ^a,h   more..

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; LENTIVIRUS VECTOR; LIPID; MICRORNA 34A; NOTCH1 RECEPTOR; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BCL2 GENE; BONE MARROW CELL; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER SURVIVAL; CDK6 GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESEARCH; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NOTCH1 GENE; PRIORITY JOURNAL; PROTEIN TARGETING; STROMA CELL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; HUMANS; LENTIVIRUS; MALE; MICE; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84869238270     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1708     Document Type: Article

References (52)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011;6:249-74.
2. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011;17:1264-77.
3. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8:479-91.
4. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48.
5. Tassone P, Tagliaferri P, Rossi M, Gaspari M, Terracciano R, Venuta S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur J Cancer 2006;42:1530-8. (Pubitemid 44118767)
6. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:757-67.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
8. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
9. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004. (Pubitemid 38327724)
10. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
11. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
12. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89.
13. Pichiorri F, De Luca L, Aqeilan RI. MicroRNAs: new players in multiple myeloma. Frontiers in genetics 2011;2:22.
14. Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012;12:823-37.
15. Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer 2012;118:878-87.
16. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, et al. Promises and challenges of microRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:838-46.
17. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-80.
18. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18:367-81.
19. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Frontiers Genet 2012;3:120.
20. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7:2591-600.
21. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17:193-9.
22. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010;31:745-50.
23. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007;26:5017-22. (Pubitemid 47172643)
24. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-307. (Pubitemid 47176893)
25. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-52. (Pubitemid 46856245)
26. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4. (Pubitemid 47014436)
27. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93. (Pubitemid 47327945)
28. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 2007;104:15472-7. (Pubitemid 47502941)
29. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-43. (Pubitemid 46856247)
30. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009;4:e6816.
31. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009;8:712-5.
32. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
33. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923-30.
34. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:1116-22.
35. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W, et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2001;2:42-53. (Pubitemid 32266385)
36. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005;106:713-6. (Pubitemid 40981270)
37. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007;13:5903-9. (Pubitemid 47583918)
38. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009;15:7144-52.
39. Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H, et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005;105:4470-6. (Pubitemid 40720796)
40. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008;14:844-52. (Pubitemid 351574906)
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
42. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008;143:520-31.
43. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011;25:707-11.
44. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, et al. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 2012;12:814-22.
45. DeWeerdt S. Animal models: towards a myeloma mouse. Nature 2011;480:S38-9.
46. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8. (Pubitemid 38174664)
47. Lionetti M, Neri A. Unpublished results.
48. Jimenez-Zepeda VH, Dominguez-Martinez VJ. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol 2009;89:259-68.
49. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22:1044-52. (Pubitemid 351689887)
50. Lloveras E, Granada I, Zamora L, Espinet B, Florensa L, Besses C, et al. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genet Cytogenet 2004;148:71-6. (Pubitemid 38018883)
51. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007;21:582-4.
52. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-40. (Pubitemid 41510761)